A Phase I/II Study of Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan as a Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation in Patients With Advanced Multiple Myeloma.

Trial Profile

A Phase I/II Study of Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan as a Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation in Patients With Advanced Multiple Myeloma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Thalidomide (Primary) ; Bortezomib; Dexamethasone; Melphalan
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms MelVelThal; Thal/Mel/Vel
  • Most Recent Events

    • 07 Jun 2016 Status changed from active, no longer recruiting to completed, according to the results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Results of an updated analysis of 2 studies (NCT00784823; n=29 and NCT01242267; n=32) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 16 Oct 2015 Planned End Date changed from 1 Nov 2014 to 1 Nov 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top